Clinical Trial Update: HuMax-CD20 in Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that the Phase 1/Phase 2 study of HuMax-CD20 (ofatumumab) for Chronic Lymphocytic Leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• HuMax-CD20 (ofatumumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN